At its Pharma Day, Swiss pharmaceutical giant Roche Holdings AG (OTC:RHHBY) outlined five priority therapeutic areas: neurology, oncology and hematology, immunology, ophthalmology, and cardiovascular, renal, and metabolism diseases.
The company shared an ‘initial set of assets designated for acceleration based on exceptional potential.’
To maximize potential, the company plans to expedite enrollment with additional clinical trial sites, reallocate resources, and expand into additional indications.
Also Read: Roche Misses Out On Weight-Loss Blockbuster Drug, Now Playing Catch-Up In Booming Market.
The selected fast-tracked programs include:
CT-388 (RG6640) for obesity entered the Phase 2 stage of development in patients with or without type 2 diabetes and comorbidities.
Roche expects a commercial launch for CT-388 beyond 2028.
Trontinemab is currently in Phase 2 for Alzheimer’s. ...
